Adjuvant Autologous Tumour Cell-Lysate Vaccine versus No Adjuvant Treatment in Patients with M0 Renal Cell Carcinoma after Radical Nephrectomy: 3-Year Interim Analysis of a German Multicentre Phase-III Trial Cited by

Fol. Biol. 2003, 49, 69-73

https://doi.org/10.14712/fb2003049020069

Adjuvant Autologous Tumour Cell-Lysate Vaccine versus No Adjuvant Treatment in Patients with M0 Renal Cell Carcinoma after Radical Nephrectomy: 3-Year Interim Analysis of a German Multicentre Phase-III Trial

Christian Doehn¹, A. Richter², W. Lehmacher³, D. Jocham¹

¹Department of Urology, University of Lübeck Medical School, Lübeck, Germany
²Department of Urology, St. Georg Hospital Leipzig, Leipzig, Germany
³Institute for Medical Statistics, University of Cologne Medical School, Cologne, Germany

Received January 2003
Accepted February 2003

Crossref Cited-by Linking

Bai Yangyang, Li Songchao, Jia Zhankui, Ding Yinghui, Gu Chaohui, Yang Jinjian: Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review. Urologic Oncology: Seminars and Original Investigations 2018, 36, 79.e1. <https://doi.org/10.1016/j.urolonc.2017.10.001>